Adding my position in $AMRN at $17.428. The stock looks cheap.

Amarin events:
– June (or later …): EU/EMA submission
– July (late) / August (early): AdCom (if any)
– August (1st week): 10-Q / Q2 2019
– September (in or before): FDA decision regarding sNDA
– November (1st week): 10-Q / Q3 2019
– November (in or before): Health Canada decision…Read More

Entering $AMRN at $17.915. The stock looks bullish. The Company’s first drug, Vascepa (icosapent ethyl) is FDA-approved in the United States for treatment of patients with very high triglyceride levels (TG ≥500 mg/dL). The drug is also available by prescription in Lebanon and the United Arab Emirates. Amarin’s commercial partners are pursu…Read More

$AMRN – Big dump today,,,, Why or just no news??